Abstract

RECENT ADVANCEMENTSIN NANOTECHNOLOGY BASED DRUG DELIVERY FOR THE MANAGEMENT OF CARDIOVASCULAR DISEASE

Aishwarya S. Shinde*, Yogesh B. Raut, Sanjay K. Bais

ABSTRACT

Cardiovascular diseases (CVDs) remain the leading global cause of mortality, imposing a major health and economic burden. Conventional therapeutic strategies are limited by poor bioavailability, short half-lives, and adverse systemic effects. Nanotechnology-based drug delivery systems (NDDSs) have emerged as a promising approach to overcome these limitations. Nanoparticles—including liposomes, micelles, polymers, dendrimers, and metal-based carriers—offer enhanced pharmacokinetics, controlled release, and site-specific targeting, thereby improving therapeutic efficacy and minimizing toxicity. In addition to therapy, nanomaterials provide advanced diagnostic opportunities through molecular imaging modalities such as MRI, PET/SPECT, CT, and ultrasound, enabling early detection and precision monitoring of CVDs. Applications of nanoformulations in atherosclerosis, hypertension, myocardial infarction, thrombosis, and stroke have demonstrated significant potential in both preclinical and translational research. Collectively, nanomedicine offers an integrated platform for the prevention, diagnosis, and treatment of cardiovascular disorders, representing a transformative shift toward personalized and precision cardiovascular care.

Keywords: Nanomedicine, nanotechnology, metal-organic frameworks, nanoparticles and cardiovascular disorders.